651 related articles for article (PubMed ID: 28471727)
21. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
[TBL] [Abstract][Full Text] [Related]
23. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Rosenberg JE; Park SH; Kozlov V; Dao TV; Castellano D; Li JR; Mukherjee SD; Howells K; Dry H; Lanasa MC; Stewart R; Bajorin DF
J Clin Oncol; 2023 Jan; 41(1):43-53. PubMed ID: 35737919
[TBL] [Abstract][Full Text] [Related]
24. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
[TBL] [Abstract][Full Text] [Related]
25. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E
Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796
[TBL] [Abstract][Full Text] [Related]
26. Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
Kim YN; Joung JG; Park E; Kim JW; Lee JB; Lim J; Kim S; Choi CH; Kim HS; Chung J; Kim BG; Lee JY
Int J Cancer; 2023 Dec; 153(12):2032-2044. PubMed ID: 37602928
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; de Bono JS; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; De Grève J; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1096-1107. PubMed ID: 31637669
[TBL] [Abstract][Full Text] [Related]
28. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
[TBL] [Abstract][Full Text] [Related]
29. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
[TBL] [Abstract][Full Text] [Related]
30. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
Poveda A; Oaknin A; Romero I; Guerrero-Zotano A; Fariñas-Madrid L; Rodriguez-Freixinos V; Mallol P; Lopez-Reig R; Lopez-Guerrero JA
Sci Rep; 2021 Feb; 11(1):4433. PubMed ID: 33627685
[TBL] [Abstract][Full Text] [Related]
31. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
32. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN; Moore K; Chon HS; Lee JY; Thomes Pepin J; Sundborg M; Shai A; de la Garza J; Nishio S; Gold MA; Wang K; McIntyre K; Tillmanns TD; Blank SV; Liu JH; McCollum M; Contreras Mejia F; Nishikawa T; Pennington K; Novak Z; De Melo AC; Sehouli J; Klasa-Mazurkiewicz D; Papadimitriou C; Gil-Martin M; Brasiuniene B; Donnelly C; Del Rosario PM; Liu X; Van Nieuwenhuysen E;
J Clin Oncol; 2024 Jan; 42(3):283-299. PubMed ID: 37864337
[TBL] [Abstract][Full Text] [Related]
33. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
Chen EX; Jonker DJ; Siu LL; McKeever K; Keller D; Wells J; Hagerman L; Seymour L
Invest New Drugs; 2016 Aug; 34(4):450-7. PubMed ID: 27075016
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
[TBL] [Abstract][Full Text] [Related]
35. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
[TBL] [Abstract][Full Text] [Related]
36. Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
Ahn MJ; Bondarenko I; Kalinka E; Cho BC; Sugawara S; Gálffy G; Shim BY; Kislov N; Nagarkar R; Demedts I; Gans SJM; Mendoza Oliva D; Stewart R; Lai Z; Mann H; Shi X; Hussein M
J Thorac Oncol; 2023 Nov; 18(11):1594-1606. PubMed ID: 37390980
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
[TBL] [Abstract][Full Text] [Related]
38. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
[TBL] [Abstract][Full Text] [Related]
39. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Lee JM; Hays JL; Annunziata CM; Noonan AM; Minasian L; Zujewski JA; Yu M; Gordon N; Ji J; Sissung TM; Figg WD; Azad N; Wood BJ; Doroshow J; Kohn EC
J Natl Cancer Inst; 2014 Jun; 106(6):dju089. PubMed ID: 24842883
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; de Bono JS; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1117-1128. PubMed ID: 31667659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
